Lenvaxen is presented on this website as a lenvatinib product in 4 mg and 10 mg strengths.
Product identity
| Product characteristic | Information |
|---|---|
| Product | Lenvaxen |
| Active ingredient | Lenvatinib |
| Strengths | 4 mg and 10 mg |
| Drug class | Receptor tyrosine kinase inhibitor |
| Therapeutic category | Antineoplastic |
| Route | Oral, subject to product documentation |
| Reference product | LENVIMA |
| Original developer of lenvatinib | Eisai |
| Specific Lenvaxen manufacturer | Everest Pharmaceuticals Ltd. |
Lenvatinib inhibits several receptor tyrosine kinase pathways, including VEGFR, FGFR, RET, KIT and PDGFRα signaling.
Reference product
LENVIMA is the established reference brand for lenvatinib. Eisai discovered and developed lenvatinib.
Regulatory information
The regulatory status of the specific Lenvaxen-branded product.
Approved indications for lenvatinib vary between regulatory jurisdictions. U.S. and European indications are not identical.
Safety
Lenvatinib can cause serious adverse reactions, including hypertension, cardiac dysfunction, arterial thromboembolism, hepatotoxicity, renal impairment, proteinuria, bleeding and other complications.
Product verification
The actual package, manufacturer and authorization documentation should be checked before use. No Lenvaxen-specific authentication system should be claimed without verification.